Methods of treating nonalcoholic steatohepatitis comprising administering an anti-human beta klotho antibody or binding fragment thereof
The present disclosure provides binding proteins, such as antibodies and binding fragments thereof, that bind beta klotho, including human beta klotho, and methods of their use, including in the treatment of nonalcoholic steatohepatitis. The present disclosure also provides exemplary specific sequences of complementarity determining regions, variable regions, heavy chains, and light chains of the antibodies and/or binding fragments thereof.
1. A method of treating nonalcoholic steatohepatitis (NASH) in a human subject, the method comprising administering to the human subject an effective amount of an antibody or binding fragment thereof that binds human beta klotho, wherein the antibody or binding fragment comprises:
(a) a heavy chain variable region (VH) comprising a VH complementarity determining region (CDR)1 comprising the amino acid sequence of SEQ ID NO:12, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:2, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:3; and
(b) a light chain variable region (VL) comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:4, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:6.
2. The method of claim 1 , wherein the VH comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:271 and the VL comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:276.
3. The method of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO:271 and the VL comprises the amino acid sequence of SEQ ID NO:276.
4. The method of claim 1 , wherein the antibody or binding fragment thereof is a humanized antibody.
5. The method of claim 1 , wherein the antibody is an IgG1 antibody, an IgG2 antibody, or an IgG4 antibody.
6. The method of claim 1 , wherein the human subject has Type 2 diabetes, obesity, dyslipidemia, cardiovascular disease, and/or metabolic syndrome.
7. The method of claim 1 , wherein the method further comprises administering at least one additional therapeutic agent.
8. The method of claim 7 , wherein the at least one additional therapeutic agent is selected from the group consisting of: biguanides, sulphonylureas, thiazolidinediones, GLP-1 analogs, PPAR gamma agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, bromocriptine, bile acid sequestrants, insulin, alpha glucosidase inhibitors, metformin, SGLT-2 inhibitors, appetite suppressants, and weight loss drugs.
9. A method of treating NASH in a human subject, the method comprising administering to the human subject an effective amount of an antibody that binds human beta klotho, wherein the antibody comprises a heavy chain comprising amino acids 23-472 of SEQ ID NO:317 and a light chain comprising amino acids 23-240 of SEQ ID NO:319.
10. The method of claim 9 , wherein the human subject has Type 2 diabetes, obesity, dyslipidemia, cardiovascular disease, and/or metabolic syndrome.
11. The method of claim 9 , wherein the method further comprises administering at least one additional therapeutic agent.
12. The method of claim 11 , wherein the at least one additional therapeutic agent is selected from the group consisting of: biguanides, sulphonylureas, thiazolidinediones, GLP-1 analogs, PPAR gamma agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, bromocriptine, bile acid sequestrants, insulin, alpha glucosidase inhibitors, metformin, SGLT-2 inhibitors, appetite suppressants, and weight loss drugs.
13. A method of treating NASH in a human subject, the method comprising administering to the human subject an effective amount of an antibody or binding fragment thereof that binds human beta klotho, wherein the antibody or binding fragment thereof comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the amino acid sequence of SEQ ID NO:271 and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the amino acid sequence of SEQ ID NO:276.
14. The method of claim 13 , wherein the method further comprises administering at least one additional therapeutic agent.
15. The method of claim 14 , wherein the at least one additional therapeutic agent is selected from the group consisting of: biguanides, sulphonylureas, thiazolidinediones, GLP-1 analogues, PPAR gamma agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, bromocriptine, bile acid sequestrants, insulin, alpha glucosidase inhibitors, metformin, SGLT-2 inhibitors, appetite suppressants, and weight loss drugs.
16. The method of claim 13 , wherein:
(a) the VH CDR1 comprises the amino acid sequence of SEQ ID NO:1, the VH CDR2 comprises the amino acid sequence of SEQ ID NO:2, the VH CDR3 comprises the amino acid sequence of SEQ ID NO:3, the VL CDR1 comprises the amino acid sequence of SEQ ID NO:4, the VL CDR2 comprises the amino acid sequence of SEQ ID NO:5, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO:6;
(b) the VH CDR1 comprises the amino acid sequence of SEQ ID NO:7, the VH CDR2 comprises the amino acid sequence of SEQ ID NO:8, the VH CDR3 comprises the amino acid sequence of SEQ ID NO:9, the VL CDR1 comprises the amino acid sequence of SEQ ID NO:10, the VL CDR2 comprises the amino acid sequence of SEQ ID NO:11, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO:6;
(c) the VH CDR1 comprises the amino acid sequence of SEQ ID NO:13, the VH CDR2 comprises the amino acid sequence of SEQ ID NO:14, the VH CDR3 comprises the amino acid sequence of SEQ ID NO:15, the VL CDR1 comprises the amino acid sequence of SEQ ID NO:16, the VL CDR2 comprises the amino acid sequence of SEQ ID NO:11, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO:17;
(d) the VH CDR1 comprises the amino acid sequence of SEQ ID NO:18, the VH CDR2 comprises the amino acid sequence of SEQ ID NO:19, the VH CDR3 comprises the amino acid sequence of SEQ ID NO:20, the VL CDR1 comprises the amino acid sequence of SEQ ID NO:21, the VL CDR2 comprises the amino acid sequence of SEQ ID NO:22, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO:23; or
(e) the VH CDR1 comprises the amino acid sequence of SEQ ID NO:1, the VH CDR2 comprises the amino acid sequence of SEQ ID NO:24, the VH CDR3 comprises the amino acid sequence of SEQ ID NO:3, the VL CDR1 comprises the amino acid sequence of SEQ ID NO:4, the VL CDR2 comprises the amino acid sequence of SEQ ID NO:5, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO:6.
17. The method of claim 13 , wherein:
the VH CDR1 comprises the amino acid sequence of SEQ ID NO:1, the VH CDR2 comprises the amino acid sequence of SEQ ID NO:2, the VH CDR3 comprises the amino acid sequence of SEQ ID NO:3, the VL CDR1 comprises the amino acid sequence of SEQ ID NO:4, the VL CDR2 comprises the amino acid sequence of SEQ ID NO:5, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO:6.
18. The method of claim 13 , wherein the VH comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:271 and the VL comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:276.
19. The method of claim 13 , wherein the antibody or binding fragment thereof is a humanized antibody.
20. The method of claim 13 , wherein the antibody is an IgG1 antibody, an IgG2 antibody, or an IgG4 antibody.
21. The method of claim 13 , wherein the human subject has Type 2 diabetes, obesity, dyslipidemia, cardiovascular disease, and/or metabolic syndrome.